Interferon-Inducible Mx Promoter-Driven, Long-Term Transgene Expression System of Interferon-β for Cancer Gene Therapy

2016 ◽  
Vol 27 (11) ◽  
pp. 936-945 ◽  
Author(s):  
Atsushi Hamana ◽  
Yuki Takahashi ◽  
Makiya Nishikawa ◽  
Yoshinobu Takakura
Keyword(s):  
Gene Therapy ◽  
Transgene Expression ◽  
Expression System ◽  
Cancer Gene Therapy ◽  
Cancer Gene ◽  
Interferon Β

ENHANCED TRANSGENE EXPRESSION IN ANDROGEN INDEPENDENT PROSTATE CANCER GENE THERAPY BY TAXANE CHEMOTHERAPEUTIC AGENTS

2002 ◽  
Vol 167 (1) ◽  
pp. 339-346 ◽  
Author(s):  
YINGMING LI ◽  
TAKATSUGU OKEGAWA ◽  
DONALD P. LOMBARDI ◽  
EUGENE P. FRENKEL ◽  
JER-TSONG HSIEH
Keyword(s):  
Prostate Cancer ◽  
Gene Therapy ◽  
Transgene Expression ◽  
Cancer Gene Therapy ◽  
Chemotherapeutic Agents ◽  
Cancer Gene ◽  
Androgen Independent

scholarly journals 625: Enhanced Transgene Expression in Urothelial Cancer Gene Therapy with Trani Last

2006 ◽  
Vol 175 (4S) ◽  
pp. 201-202
Author(s):  
Takatsugu Okegawa ◽  
Kikuo Nutahara ◽  
Eiji Higashihara ◽  
Rey-Chen Pong ◽  
Jer-Tsang Hsieh
Keyword(s):  
Gene Therapy ◽  
Transgene Expression ◽  
Urothelial Cancer ◽  
Cancer Gene Therapy ◽  
Cancer Gene

Retroviral Vector-Producing Mesenchymal Stem Cells for Tumor Tracking and Therapeutic Gene Amplification in Suicide Cancer Gene Therapy.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 1917-1917
Author(s):  
Ryosuke Uchibori ◽  
Takashi Okada ◽  
Takayuki Ito ◽  
Masashi Urabe ◽  
Hiroaki Mizukami ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Nude Mice ◽  
Therapeutic Efficacy ◽  
Transgene Expression ◽  
Glioma Cells ◽  
Retroviral Vector ◽  
Cancer Gene Therapy ◽  
Cancer Gene ◽  
Tumor Bearing ◽  
Anti Cancer

Abstract Mesenchymal stem cells (MSCs) are known to have a tendency to accumulate at the site of tumors, and therefore can be utilized as a platform for targeted delivery of anti-cancer agents. The MSC-based targeted cancer gene therapy can enhance the therapeutic efficacy, because MSCs are considered to reach tumors including metastatic lesions and to deliver therapeutic molecules in a concentrated fashion. This targeted therapy can also reduce systemic adverse side effects, because the anti-cancer agents act locally at the site of tumors without elevating their systemic concentrations. In the present study, we developed genetically-modified MSCs that produce retroviral vectors encoding HSVtk, aiming at augmenting therapeutic efficacy of systemic suicide cancer gene therapy. The tumor tropism and anti-tumor effects of vector-producing MSCs (VP-MSCs) were examined by intravascular injection in tumor-bearing nude mice. MSCs isolated from the bone marrow of SD rats were transfected with plasmid DNA expressing luciferase alone (=non-VP-MSCs) or whole retroviral vector components (LTR-Luc or LTR-HSVtk with Gag-pol and VSV-G) (=VP-MSCs) by nucleofection. To assess tumor tropism of MSCs, nude mice were subcutaneously inoculated with 9L rat glioma cells or Rat-1 fibroblasts, and were subsequently injected with luciferase-expressing MSCs through the left ventricular cavity. The transgene expression was periodically traced by using an in vivo imaging system. As a result, the transgene expression accumulated at the site of subcutaneous 9L tumors, but undetectable at the site of Rat-1 fibroblasts. In addition, the injection of luciferase-expressing VP-MSCs caused much stronger signal of bioluminescence at the site of 9L tumors compared with luciferease-expressing non-VP-MSCs. Immunostaining study showed that luciferase-positive cells (injected MSCs and transduced glioma cells) were detected at the periphery of tumors. To evaluate the therapeutic efficacy, tumor-bearing nude mice were treated with non-VP-MSCs or VP-MSCs combined with HSVtk/GCV system and then the size of subcutaneous tumors was periodically measured. In this model experiments, tumor growth was more efficiently suppressed by injecting VP-MSCs compared with non-VP-MSCs. The present study suggests the effectiveness of VP-MSCs in suicide cancer gene therapy. The therapeutic benefit of this strategy should be further examined in orthotopic and metastatic tumor models.

Selection of microRNA for providing tumor specificity of transgene expression in cancer gene therapy

2016 ◽  
Vol 50 (2) ◽  
pp. 284-291 ◽  
Author(s):  
M. V. Shepelev ◽  
S. V. Kalinichenko ◽  
P. N. Vikhreva ◽  
I. V. Korobko
Keyword(s):  
Gene Therapy ◽  
Transgene Expression ◽  
Cancer Gene Therapy ◽  
Cancer Gene ◽  
Tumor Specificity ◽  
Selection Of
Sign in / Sign up

Export Citation Format

Share Document